Cross-border biotech deals between China and the United States are encountering increasing geopolitical and regulatory challenges, yet industry experts expect overall collaboration and deal volumes to continue rising despite added complexities.
- US legislative proposals to screen biotech investments raise regulatory burdens.
- Out-licensing deals between Chinese biotechs and Western pharma expected to surpass $240 billion in 2026.
- Political risk limits deal structures; Big Pharma remains dominant cross-border participant.
What happened
The United States has intensified efforts to control technology transfers and investments in the Chinese biotechnology sector, introducing measures such as the proposed Biosecure Act and BINSA legislation. These initiatives aim to subject partnerships, licensing deals, and equity investments involving Chinese biotech companies to more rigorous review by US authorities, especially the Treasury Department.
Despite these tightening controls, large-scale collaborations continue to be forged. Deals like Jiangsu Hengrui Pharmaceutical’s $15.2 billion agreement with Bristol Myers Squibb and Innovent Biologics’ $10.5 billion partnership with Pfizer highlight the ongoing robust commercial exchange. Analysts estimate the total value of China-Western out-licensing agreements to reach around $240 billion in 2026, reflecting sustained deal momentum even amid geopolitical challenges.
Why it matters
These regulatory developments represent a shift toward increased geopolitical scrutiny of cross-border biotech transactions, adding complexity and selective pressures to deal-making processes. This heightened oversight may reduce the number and scale of certain transactions, particularly those involving complicated investment structures like 'NewCo' joint ventures that retain equity stakes in China.
Nonetheless, the enduring strategic value of Chinese innovation and lower drug development costs underpin continued Western interest. Chinese early-stage drug assets, often valued at significant discounts to global peers, remain attractive for multinational pharmaceutical companies seeking cost-efficient pipelines and quicker development timelines. As a result, despite the political headwinds, collaborations are expected to persist and grow under more cautious and politically mindful frameworks.
What to watch next
Market observers should monitor the legislative progress of the Biosecure Act and BINSA in the US Congress, as enactment will formalize more stringent screening mechanisms influencing deal structures and participant risk assessments. Additional regulatory measures or bilateral diplomatic developments could further impact how Chinese biotech assets are licensed or invested in by Western firms.
Industry participants and investors should also keep an eye on Chinese government policies, particularly increased protections over proprietary biomedical data and intellectual property, which add another layer of negotiation complexity for foreign partners. The continued dominance of large pharmaceutical companies in facilitating these transnational collaborations will be notable, alongside potential pushback by multinational firms advocating for reduced investment frictions.